{"id":207939,"name":"INCYTE CORPORATION","slug":"incyte-corporation","state":"DE","country":"United States of America","description":"","totalSpending":6770000,"filings":25,"yearlySpending":[{"year":2021,"income":1070000},{"year":2022,"income":1030000},{"year":2023,"income":1740000},{"year":2024,"income":1310000},{"year":2025,"income":1620000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"CPT","display":"Copyright/Patent/Trademark"}],"firms":["INCYTE CORPORATION"],"lobbyists":["MELISSA BANASHAK","JENNIFER BARBLAN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Issues related to 340B (contract pharmacy provisions); drug pricing; out of pocket costs in Medicare Part D and importation","Issues related to 340B (contract pharmacy provisions); Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform; Issues related to Part B refunds for discar","Issues related to 340B (contract pharmacy provisions); Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform","Issues related to tax reform; Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform","Issues related to tax reform; Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform"]}